Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
https://summit.news/2021/11/04/italian-institute-of-health-drastically-reduces-its-official-covid-death-toll-number/
Italian newspaper Il Tempo reports that the Institute has revised downward the number of people who have died from COVID rather than with COVID from 130,000 to under 4,000.
Of the of the 130,468 deaths registered as official COVID deaths since the start of the pandemic, only 3,783 are directly attributable to the virus alone.
"150 nasal samples were identified as negative with the AffiDX® SARS-CoV-2 Antigen LFD matching their former 150 negative RTqPCR results. Therefore, there was 100% correlation for the detection of negative samples as shown in table 3, with no false positives observed."
Hopefully the same teams in Madrid are leading HUA. Excellent find.
Thread
See new Tweets
Conversation
RAH
@TheEthicalTout
LFT demand (without covid) was another reason for my 117p purchase of #AVCT yesterday. Most investors are focussed on either AffiDx or AVA6000. However, if one looks beyond these short term drivers to the post-covid LFT potential, I think they will be pleasantly surprised.
8:08 AM · Oct 26, 2021·Twitter for iPad
3
Retweets
1
Quote Tweet
10
Likes
RAH
@TheEthicalTout
·
32m
Replying to
@TheEthicalTout
The size and the scope of the non-Covid LFT market is expansive. All driven by Affimers. Some assays in this area are under licence (such as B12 w/the licence held by Abbott) but others are not. This presents huge opportunity.